Fusogenic liposomes effectively deliver resveratrol to the cerebral microcirculation and improve endothelium‐dependent neurovascular coupling responses in aged mice.

Abstract

Adjustment of cerebral blood flow (CBF) to the increased oxygen and nutrient demands of active brain regions via neurovascular coupling (NVC) has an essential role in maintenance of healthy cognitive function. In advanced age, cerebromicrovascular oxidative stress and endothelial dysfunction impair neurovascular coupling, contributing to age‐related cognitive decline. Recently we developed a resveratrol (3,4′,5‐trihydroxystilbene)‐containing fusogenic liposome (FL‐RSV)‐based molecular delivery system that can effectively target cultured cerebromicrovascular endothelial cells, attenuating age‐related oxidative stress. To assess the cerebromicrovascular protective effects of FL‐RSV in vivo, aged (24‐month‐old) C57BL/6 mice were treated with FL‐RSV for four days. To demonstrate effective cellular uptake of FL‐RSV, accumulation of the lipophilic tracer dyes in cells of the neurovascular unit was confirmed using two‐photon imaging (through a chronic cranial window). NVC was assessed by measuring CBF responses (laser speckle contrast imaging) evoked by contralateral whisker stimulation. We found that NVC responses were significantly impaired in aged mice. Treatment with FL‐RSV significantly improved NVC responses by increasing NO‐mediated vasodilation. These findings are paralleled by the protective effects of FL‐RSV on endothelium‐dependent relaxation in the aorta. Thus, treatment with FL‐RSV rescues endothelial function and NVC responses in aged mice. We propose that resveratrol containing fusogenic liposomes could also be used for combined delivery of various anti‐geronic factors, including proteins, small molecules, DNA vectors and mRNAs targeting key pathways involved in microvascular aging and neurovascular dysfunction for the prevention/treatment of age‐related cerebromicrovascular pathologies and development of vascular cognitive impairment (VCI) in aging.Support or Funding InformationThis work was supported by grants the Oklahoma Center for the Advancement of Science and Technology, the Oklahoma Shared Clinical and Translational Resources (OSCTR) program funded by the National Institute of General Medical Sciences (GM104938), the NIA‐supported Geroscience Training Program in Oklahoma (T32AG052363), the Oklahoma Nathan Shock Center (P30AG050911), the Cellular and Molecular GeroScience CoBRE (1P20GM125528, sub#5337), and the NIGMS supported Center of Biomedical Research Excellence (CoBRE)..